Though long since having outgrown SBIR size standards, it is interesting to note that OraSure Technologies, Inc. (NASDAQ: OSUR), has matured to become a global leader in point-of-care and home diagnostic testing and sample collection technologies - work initiated in some measure from their SBIR involvement. Still of interest, in September 2021 it was announced that that the firm had been awarded a $109 million contract from the US Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), to build additional manufacturing capacity in the United States for InteliSwab™ COVID-19 rapid tests as part of the nation's pandemic preparedness plan. OraSure Technologies was originally formed as the result of a merger in 2000 between Epitope Inc and STC Technologies. The combined company works in the field of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Products include rapid tests for the detection of antibodies to HIV and HCV at the point of care and testing solutions for detecting various drugs of abuse. In July 2012, the Company received approval from the U.S. Food and Drug Administration for the Company's OraQuick® In-Home HIV Test for sale directly to consumers in the over-the-counter (OTC) market - making it the first and only rapid OTC HIV test approved in the U.S. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, and commercial and industrial entities. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. In 2020, Orasure acquired another SBIR firm - UrSure.
